
Zevra Therapeutics, a biopharmaceutical firm, innovates safer therapies for pain, ADHD, and CNS diseases using its proprietary LAT approach.
Zevra Therapeutics, founded to innovate in the biopharmaceutical sector, focuses on developing safer therapies for pain, ADHD, and central nervous system (CNS) diseases. Utilizing its proprietary Ligand Activated Therapy (LAT) approach, Zevra aims to create abuse-resistant opioid pain relievers and improve existing drugs to expedite development timelines. Their product portfolio includes Olpruva® and Azstarys®, targeting specific medical needs within their market focus.
Notable figures affiliated with Zevra include its leadership team and board of directors, who bring extensive industry experience. The company has achieved significant milestones, such as the acquisition of Acer Therapeutics, expanding its therapeutic reach. Zevra's impact is marked by its commitment to addressing unmet medical needs through innovative drug development, contributing to advancements in pain management and CNS disease treatment.
Similar Company

Akouos
Similar Company

Sarborg
Similar Company

Atsena Therapeutics

Trevena

Aquestive Therapeutics
aquestive.com

Zena Therapeutics

Elite Pharmaceuticals
elitepharma.com

Pacira BioSciences
pacira.com

MediciNova
medicinova.com

Lyndra
lyndra.com

Trigemina

Concentric Analgesics

Centrexion Therapeutics
centrexion.com

Heron Therapeutics
herontx.com

Tremeau Pharmaceuticals

Acadia Pharmaceuticals
acadia-pharm.com

Avalo Therapeutics
avalotx.com

Azevan Pharmaceuticals
azevan.com

Bridge Therapeutics

CervoMed
cervomed.com
Companies similar to Zevra Therapeutics include Sarborg, Atsena Therapeutics, Trevena and Aquestive Therapeutics.
Zevra Therapeutics was founded in 2006.
Zevra Therapeutics' headquarters is located in Boston, MA, US.
Zevra Therapeutics' most recent funding round was for $78M (USD) in December 2019.
As of Dec 1, 2019, Zevra Therapeutics has disclosed funding of $153.8M (USD).
Zevra Therapeutics has 40 employees as of Feb 5, 2024.